<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on January 11, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708238</url>
  </required_header>
  <id_info>
    <org_study_id>04032016</org_study_id>
    <nct_id>NCT02708238</nct_id>
  </id_info>
  <brief_title>Efficacy of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) for Infantile Colics</brief_title>
  <official_title>Efficacy of a Standardized Extract of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) Compared With Lactobacillus Reuteri (DSM 17938) and With Simethicone for the Treatment of Infantile Colic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter prospective, randomized comparative study will be conducted in infants with
      colic, according to Rome III criteria. Enrolled infants will be assigned at random to
      receive Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122), L
      reuteri DSM 17938 (108 CFU) or simethicone. Treatment will be given to subjects for 28 days
      and they will be followed for 4 weeks. Treatment success will be assessed at the end of
      study period. Daily crying and fussing times will be recorded in a structured diary, and
      maternal questionnaires will be completed to monitor changes in infant colic symptoms and
      adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, multicentre, open label, randomized, controlled trial. All
      consecutive infants diagnosed with IC, according to Rome III criteria, will be prospectively
      enrolled in a 12 months period by 3 different Pediatric Gastroenterology units: Department
      of Translational Medical Science, Section of Pediatrics, University of Naples &quot;Federico II&quot;;
      Institute of Pediatrics of the University of Foggia; Endoscopy and Gastroenterology Unit,
      Department of Pediatrics, University of Messina.

      After the enrollment, all children will be randomly assigned to receive Chamomilla L.,
      Melissa Officinalis L. and tyndallized L. Acidophilus (H122) (Group A), L reuteri DSM 17938
      (108 CFU) (Group B) or Simethicone (Group C). Treatment will be given to subjects for 28
      days. The study's primary outcome is defined as a reduction in the duration of average
      crying times, from baseline (day 0) to end of treatment (day 28). The secondary outcome
      measure is the number of participants who respond to treatment on days 28. Infants who
      experience a decrease in the daily average crying time of 50% from baseline will be
      considered as responders to the treatment. Parents will be instructed to complete a
      structured 28-day maternal diary, modified from Barr et al. in order to record the frequency
      of colic episodes and the daily crying and fussing time (in minutes), feeding schedule,
      stool frequency and characteristics, and any adverse events experienced (14). Follow-up
      visits will be conducted on study days 7, 14, 21 and 28 by the same study investigator. At
      that visit, diaries and unused study products will be returned.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Median Daily Crying Time at the End of the Treatment</measure>
    <time_frame>28 days of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Median daily crying at the end of treatment (day 28).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Responders</measure>
    <time_frame>28 days of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of responders defined as the number of patients who experienced a decrease in the daily average crying time of 50% from baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Infantile Colics</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</intervention_name>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri DSM 17938 (108 CFU)</intervention_name>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simethicone</intervention_name>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosis of IC according to Rome III criteria (2);

          2. age ≥2 weeks to 4 months;

          3. breast-fed or fomula-fed infants;

          4. term delivery (≥37 weeks gestation at birth);

          5. 5-minute Apgar score ≥7; and 6) birth weight ≥2500 g

        Exclusion Criteria:

          1. a major medical problem or acute illness;

          2. family history of atopy;

          3. history of antibiotic treatment before or during the study;

          4. history of probiotic supplementation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annamaria Staiano, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 20, 2016</lastchanged_date>
  <firstreceived_date>March 4, 2016</firstreceived_date>
  <firstreceived_results_date>April 15, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Erasmo Miele</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Infantile colics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simethicone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publication</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
Lactobacillus reuteri DSM 17938 (108 CFU)</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 20 drops four times per day of a commercially available solution
Simethicone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
Lactobacillus reuteri DSM 17938 (108 CFU)</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 20 drops four times per day of a commercially available solution
Simethicone</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="57"/>
            <count group_id="B4" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="14" upper_limit="86"/>
                    <measurement group_id="B2" value="35" lower_limit="14" upper_limit="85"/>
                    <measurement group_id="B3" value="30" lower_limit="14" upper_limit="62"/>
                    <measurement group_id="B4" value="35" lower_limit="14" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Daily Crying Time at the End of the Treatment</title>
        <description>Median daily crying at the end of treatment (day 28).</description>
        <time_frame>28 days of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
Lactobacillus reuteri DSM 17938 (108 CFU)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 20 drops four times per day of a commercially available solution
Simethicone</description>
          </group>
        </group_list>
        <measure>
          <title>Median Daily Crying Time at the End of the Treatment</title>
          <description>Median daily crying at the end of treatment (day 28).</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="30" upper_limit="180"/>
                    <measurement group_id="O2" value="55" lower_limit="30" upper_limit="180"/>
                    <measurement group_id="O3" value="80" lower_limit="30" upper_limit="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responders</title>
        <description>Number of responders defined as the number of patients who experienced a decrease in the daily average crying time of 50% from baseline</description>
        <time_frame>28 days of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
Lactobacillus reuteri DSM 17938 (108 CFU)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 20 drops four times per day of a commercially available solution
Simethicone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders</title>
          <description>Number of responders defined as the number of patients who experienced a decrease in the daily average crying time of 50% from baseline</description>
          <units>number of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
Lactobacillus reuteri DSM 17938 (108 CFU)</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 20 drops four times per day of a commercially available solution
Simethicone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The absence of a placebo group and the open label design represent the main limitations of this study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Annamaria Staiano</name_or_title>
      <organization>Department of Translational Medical Sciences, Section of Pediatrics, University of Naples &quot;Federico II&quot;</organization>
      <phone>00390817462679</phone>
      <email>staiano@unina.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
